B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.
B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.